BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, anti-viral activity and immune system defense; resistance to stress; endurance; recovery from injury, illness and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best worldwide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses. Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.”
Company profile
Ticker
BDPT
Exchange
Website
CEO
Kim D. Southworth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
APEX 8 Inc.
SEC CIK
BDPT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
10 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
1-A
Offering $200.00 k in Debt
11 Oct 23
1-Z
Offering exit report
24 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Departure of Directors or Certain Officers
6 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
DEF 14C
Information statement
28 Mar 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 152.07 k | 152.07 k | 152.07 k | 152.07 k | 152.07 k | 152.07 k |
Cash burn (monthly) | (no burn) | (no burn) | 30.74 k | 16.20 k | 18.72 k | 13.33 k |
Cash used (since last report) | n/a | n/a | 204.80 k | 107.96 k | 124.71 k | 88.83 k |
Cash remaining | n/a | n/a | -52.73 k | 44.11 k | 27.37 k | 63.24 k |
Runway (months of cash) | n/a | n/a | -1.7 | 2.7 | 1.5 | 4.7 |